| Style | Citing Format |
|---|---|
| MLA | Ameli F, et al.. "Outcome of Acute Myeloid Leukemia Treatment and Isocitrate Dehydrogenase (Idh) Mutations: A Systematic Review and Meta-Analysis Study." International Journal of Hematology-Oncology and Stem Cell Research, vol. 20, no. 2, 2026, pp. 174-188. |
| APA | Ameli F, Abdollahi A, Salarvand S, Ghasemi D (2026). Outcome of Acute Myeloid Leukemia Treatment and Isocitrate Dehydrogenase (Idh) Mutations: A Systematic Review and Meta-Analysis Study. International Journal of Hematology-Oncology and Stem Cell Research, 20(2), 174-188. |
| Chicago | Ameli F, Abdollahi A, Salarvand S, Ghasemi D. "Outcome of Acute Myeloid Leukemia Treatment and Isocitrate Dehydrogenase (Idh) Mutations: A Systematic Review and Meta-Analysis Study." International Journal of Hematology-Oncology and Stem Cell Research 20, no. 2 (2026): 174-188. |
| Harvard | Ameli F et al. (2026) 'Outcome of Acute Myeloid Leukemia Treatment and Isocitrate Dehydrogenase (Idh) Mutations: A Systematic Review and Meta-Analysis Study', International Journal of Hematology-Oncology and Stem Cell Research, 20(2), pp. 174-188. |
| Vancouver | Ameli F, Abdollahi A, Salarvand S, Ghasemi D. Outcome of Acute Myeloid Leukemia Treatment and Isocitrate Dehydrogenase (Idh) Mutations: A Systematic Review and Meta-Analysis Study. International Journal of Hematology-Oncology and Stem Cell Research. 2026;20(2):174-188. |
| BibTex | @article{ author = {Ameli F and Abdollahi A and Salarvand S and Ghasemi D}, title = {Outcome of Acute Myeloid Leukemia Treatment and Isocitrate Dehydrogenase (Idh) Mutations: A Systematic Review and Meta-Analysis Study}, journal = {International Journal of Hematology-Oncology and Stem Cell Research}, volume = {20}, number = {2}, pages = {174-188}, year = {2026} } |
| RIS | TY - JOUR AU - Ameli F AU - Abdollahi A AU - Salarvand S AU - Ghasemi D TI - Outcome of Acute Myeloid Leukemia Treatment and Isocitrate Dehydrogenase (Idh) Mutations: A Systematic Review and Meta-Analysis Study JO - International Journal of Hematology-Oncology and Stem Cell Research VL - 20 IS - 2 SP - 174 EP - 188 PY - 2026 ER - |